Clinicopathological and genetic analysis of 55 male patients with invasive breast cancer

Breast cancer is a disease most people associate with women, yet it can affect anyone with breast tissue, including men. While rare, occurring in roughly one out of every hundred breast cancer cases, male breast cancer behaves differently than the disease in women. It tends to appear later in life and often presents with distinct biological features that influence how doctors treat it. To understand these differences, scientists look at the cells under a microscope to see their shape and structure, and they also examine the chemical signals on the cell surface that tell the tumor how to grow. Perhaps most importantly, modern medicine now looks inside the cells at the genetic code itself, searching for specific errors or "typos" in the DNA that drive the cancer. Identifying these genetic changes is crucial because it allows doctors to move beyond one-size-fits-all treatments and choose therapies that target the specific weaknesses of a patient's tumor.

A team of researchers at Fudan University Shanghai Cancer Center recently set out to map these characteristics specifically for men in China. They gathered detailed information on 55 male patients diagnosed with invasive breast cancer, a type where the cancer has spread beyond the milk ducts into surrounding tissue. By combining standard medical records with advanced genetic testing, the team built a clear picture of who gets this disease, what the tumors look like, and what genetic mistakes are driving them. Their work helps fill a gap in medical knowledge, as large studies focusing specifically on the Chinese male population have been scarce until now.

The patients in this study were, on average, 67 years old, with ages ranging from 24 to 86. This confirms that the disease predominantly affects older men. When these men first noticed a problem, it was usually a lump located directly behind the nipple, a common spot for male breast tumors because men have less breast tissue overall than women. The tumors were generally small, with a median size of 1.7 centimeters. Despite their small size, the researchers found that the cancer had already spread to nearby lymph nodes in about a quarter of the patients, and in more than a third of cases, the cancer cells had invaded the tiny vessels that carry lymph fluid.

When the scientists looked at the tissue under a microscope, the results were strikingly uniform. Nearly all of the tumors, about 93 percent, were a type called invasive carcinoma of no special type. This is the most common form of breast cancer, but in men, it is almost the only form seen. The researchers also checked the chemical "flags" on the surface of the cancer cells. These flags determine which drugs will work. The study found that almost every single tumor, 98 percent, was "luminal," meaning it relied heavily on hormones like estrogen to grow. In fact, only one patient had a tumor that did not rely on hormones, and no patients had the aggressive "triple-negative" type that lacks all three major hormone receptors. This high rate of hormone dependence suggests that hormone-blocking therapies, which are standard for many female patients, are likely to be very effective for men as well.

To understand the root causes of these tumors, the researchers performed a deep genetic scan on 32 of the patients. They examined 511 different genes to find errors that might be driving the cancer. They found that about a third of the patients had at least one significant genetic change. The most common error was a mutation in a gene called PIK3CA, which acts as a switch for cell growth; this was found in nearly 19 percent of the sequenced cases. Another critical finding involved the BRCA2 gene, which helps repair damaged DNA. In four patients, the researchers found a harmful mutation in this gene that was present in their blood, meaning it was inherited from their parents rather than acquired during their lifetime. This is a significant discovery because it implies that these men and their families may face higher risks for other cancers and should consider genetic counseling.

The study also identified other genetic changes, such as extra copies of genes that encourage cell division, including FGFR1, which was amplified in 12.5 percent of the cases. While the researchers did not test these specific patients with new drugs, the presence of these mutations suggests that future treatments targeting these specific genetic pathways could be beneficial. The team also noted that while many patients had variations in genes like TP53 and BRCA1, these were not the harmful, disease-causing types, but rather common variations that did not necessarily drive the cancer.

The overall picture that emerges from this research is one of a disease that, while rare, follows a very predictable pattern in men. It strikes older individuals, usually presents as a single lump behind the nipple, and is almost always driven by hormones. The genetic landscape is also distinct, with a notable frequency of inherited errors in the BRCA2 gene and specific mutations in the PIK3CA gene. These findings provide a solid foundation for doctors to make more informed decisions. By knowing that a male patient's tumor is likely hormone-driven and by checking for these specific genetic markers, medical teams can tailor treatment plans that are more precise and potentially more effective than the standard approaches used for women. This study does not claim to have solved the mystery of male breast cancer, but it offers a clear, detailed map of the terrain, guiding the way toward better care for this vulnerable group of patients.